Loading...
TARA logo

Protara Therapeutics, Inc.NasdaqGM:TARA Rapporto sulle azioni

Cap. di mercato US$276.5m
Prezzo delle azioni
US$4.80
US$26.57
81.9% sottovalutato sconto intrinseco
1Y51.9%
7D10.6%
1D
Valore del portafoglio
​
Vista

Protara Therapeutics, Inc.

Report azionario NasdaqGM:TARA

Capitalizzazione di mercato: US$276.5m

Protara Therapeutics (TARA) Panoramica del titolo

Protara Therapeutics, Inc. è una società biofarmaceutica in fase clinica che si occupa di promuovere terapie trasformative per il trattamento del cancro e delle malattie rare. Maggiori dettagli

TARA analisi fondamentale
Punteggio fiocco di neve
Valutazione5/6
Crescita futura2/6
Prestazioni passate0/6
Salute finanziaria6/6
Dividendi0/6

Premi

Negoziato a 97.7% al di sotto della nostra stima del suo valore equo

Si prevede che i ricavi cresceranno 65.99% all'anno

Gli analisti concordano sul fatto che il prezzo delle azioni salirà di 453.6%

Analisi del rischio

Realizza un fatturato inferiore a 1 milione di dollari ( $0 )

Gli azionisti sono stati sostanzialmente diluiti nell'ultimo anno

Attualmente non redditizio e non si prevede che diventerà redditizio nei prossimi 3 anni


TARA Community Fair Values

Create Narrative

See what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Concorrenti di Protara Therapeutics, Inc.

Storia dei prezzi e prestazioni

Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Protara Therapeutics
Prezzi storici delle azioni
Prezzo attuale dell'azioneUS$4.80
Massimo di 52 settimaneUS$7.82
Minimo di 52 settimaneUS$2.77
Beta1.53
Variazione di 1 mese-6.43%
Variazione a 3 mesi-19.46%
Variazione di 1 anno51.90%
Variazione a 3 anni68.42%
Variazione a 5 anni-48.77%
Variazione dall'IPO-84.00%

Notizie e aggiornamenti recenti

Recent updates

Seeking Alpha • Dec 04

Protara Therapeutics: End Of 2025 Proving Eventful Indeed

Summary Protara Therapeutics maintains strong momentum with TARA-002, showing durable, high complete response rates in NMIBC and promising efficacy in lymphatic malformations. TARA-002’s 6-month complete response rate of 69% in BCG-naive NMIBC patients and 100% clinical success in lymphatic malformations reinforce its competitive positioning. With over two years of cash runway, TARA is well-capitalized to reach pivotal regulatory and clinical milestones without near-term dilution risk. I maintain a 'Buy' rating on TARA, though with tempered conviction, as positive data and market opportunity are balanced by evolving competition and volatility. Read the full article on Seeking Alpha
Articolo di analisi • Jul 10

We Think Protara Therapeutics (NASDAQ:TARA) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Mar 28

Protara Therapeutics: Speculative Buy On Promising TARA-002 Trial Results

Summary TARA’s leading candidate is TARA-002, which so far looks like a promising immune-stimulating therapy derived from OK-432 (Picibanil). Their recent Phase 2 ADVANCED-2 trial also showed favorable results in NMIBC, with a notable 72% complete response rate at six months. TARA’s pipeline also has IV Choline, which could target unmet needs in patients requiring parenteral nutrition, and it has no other FDA-approved alternatives. I also believe their cash reserves and recent raise secure their runway, at least until 2027. So, even though TARA remains a relatively speculative microcap, I believe it trades at a compelling valuation in light of its potential. So I rate it a “Buy” at these levels. Read the full article on Seeking Alpha
Articolo di analisi • Mar 07

We're Hopeful That Protara Therapeutics (NASDAQ:TARA) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Dec 10

Protara: Six-Month NMIBC Treatment Data Bodes Well For Mid-2025 Catalyst

Summary Initial data from the phase 2 ADVANCED-2 study, using TARA-002 for the treatment of patients with non-muscle invasive bladder cancer, is expected by mid-2025. The global bladder cancer market size is expected to reach $5.4 billion by 2034. Initial results from the phase 2 STARBORN-1 study, using TARA-002 for the treatment of pediatric patients with macroystic and mixed cystic LMs, are expected in the 1st half of 2025. Dosing of first patients in phase 3 THRIVE-3 study, using IV choline chloride for parenteral support patients, are expected in Q1 of 2025. The company had $81.5 million in cash as of September 30th of 2024; Despite the cash runway, management chose to raise approximately $100 million through an underwritten public offering. Read the full article on Seeking Alpha
Articolo di analisi • Nov 22

Here's Why We're Watching Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, Protara Therapeutics...
Articolo di analisi • Aug 08

Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Feb 22

Protara: A Bombed Out Biotech With A Very Positive Skew

Summary Protara Therapeutics is developing therapies for cancer and rare diseases, with a focus on non-muscle invasive bladder cancer and lymphangiomas. The company's main candidate, TARA-002, is being tested in phase 2 trials for NMIBC and lymphangiomas, with preliminary results expected in H1 2024. Protara is trading below its cash value, presenting a potential undervaluation opportunity if its phase 2 trials are successful. Read the full article on Seeking Alpha
Articolo di analisi • Dec 16

Here's Why We're Watching Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Articolo di analisi • Apr 22

We Think Protara Therapeutics (NASDAQ:TARA) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Oct 13

The Prognosis For Protara Therapeutics

Summary We put small biopharma concern Protara Therapeutics in the spotlight today for the first time in more than 18 months. The stock has seen some small insider buying throughout 2022 and the shares sell for less than 50% of the company's net cash on the balance sheet. An investment analysis follows in the paragraphs below. Men are never convinced of your reasons, of your sincerity, of the seriousness of your sufferings, except by your death. So long as you are alive, your case is doubtful; you have a right only to their skepticism.”― Albert Camus We took our first look at Protara Therapeutics (TARA) back in the first quarter of 2021. No one on Seeking Alpha has provided coverage on the company since. Given I get an occasional question around Protara, today we are going to circle back on this small biopharma concern. An updated analysis follows below. Seeking Alpha Company Overview: Protara Therapeutics was formed when Proteon Therapeutics merged with privately held ArTara Therapeutics in late 2019. The company is based in New York City and is focused on developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs. The stock currently trades around $3.50 a share and has an approximate market capitalization of $40 million. March Company Presentation The company's pipeline consists mainly of one key compound in development. Protara's lead pipeline asset is TARA-002. It is in development for the treatment of lymphatic malformations [LMs] and non-muscle invasive bladder cancer (NMIBC). It has a Rare Pediatric Disease designation for LMs. March Company Presentation The company received preliminary guidance regarding a development path for TARA-002 in lymphatic malformations in the first quarter of this year from the FDA. March Company Presentation Management's plan is to initiate a Phase 2 clinical trial in this indication, subject to alignment with FDA on the clinical trial protocol. LMs are rare, congenital malformations of lymphatic vessels resulting in the failure of these structures to connect or drain into the venous system. Most LMs are present in the head and neck region and are diagnosed in early childhood during the period of active lymphatic growth. March Company Presentation The first patient was dosed in Phase 1 trial evaluating TARA-002 to treat NMIBC in the first quarter of 2022. NMIBC represents 80% of all bladder cancer, which is the sixth most frequent time of cancer in the world. Approximately 65,000 patients are diagnosed with NMIBC in the United States each year. March Company Presentation When TARA-002 is administered, it is hypothesized that innate and adaptive immune cells within the cyst or tumor are activated and produce a strong immune cascade. TARA-002 was developed from the same master cell bank of genetically distinct group A Streptococcus pyogenes as OK-432, a broad immunopotentiator marketed as Picibanil® in Japan and Taiwan. March Company Presentation The company is also doing a prospective study to enhance its understanding of the incidence of Intestinal Failure Associated Liver Disease or IFALD in patients dependent on parenteral nutrition that remains ongoing. The company did get a key patent for this potential IV Choline Chloride program in April of this year. This candidate is an investigational, intravenous (IV) phospholipid substrate replacement therapy. There doesn't seem to be much movement in this program since we last looked at Protara in February of 2021. March Company Presentation Analyst Commentary & Balance Sheet: The company gets sparse commentary on Wall Street. In 2022, Oppenheimer ($32 price target), H.C. Wainwright ($23 price target) and Ladenberg Thalmann ($32 price target) have maintained Buy ratings on the stock. These are the only analyst firms I can find that have chimed in around Protara so far this year. Approximately two percent of the outstanding float in the shares are currently held short. At the end of the second quarter, the company had nearly $100 million of cash and marketable securities on its balance sheet against no long term debt. Management has guided that this cash balance is sufficient to fund all planned activities until mid-2024. The company had a net loss of $8.5 million in 2Q2022.
Articolo di analisi • Sep 12

Here's Why We're Not Too Worried About Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Articolo di analisi • Mar 21

Will Protara Therapeutics (NASDAQ:TARA) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Articolo di analisi • Dec 06

Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Rendimenti per gli azionisti

TARAUS BiotechsUS Mercato
7D10.6%2.9%2.5%
1Y51.9%33.0%26.4%

Ritorno vs Industria: TARA ha superato il US Biotechs che ha restituito 33 % nell'ultimo anno.

Rendimento vs Mercato: TARA ha superato il mercato US che ha restituito 26.4 % nell'ultimo anno.

Volatilità dei prezzi

Is TARA's price volatile compared to industry and market?
TARA volatility
TARA Average Weekly Movement8.5%
Biotechs Industry Average Movement10.8%
Market Average Movement7.2%
10% most volatile stocks in US Market16.5%
10% least volatile stocks in US Market3.1%

Prezzo delle azioni stabile: TARA non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.

Volatilità nel tempo: La volatilità settimanale ( 9% ) di TARA è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

FondatoI dipendentiAMMINISTRATORE DELEGATOSito web
n/a46Jesse Sheffermanwww.protaratx.com

Protara Therapeutics, Inc. è una società biofarmaceutica in fase clinica che si occupa di promuovere terapie trasformative per il trattamento del cancro e delle malattie rare. Il programma principale dell'azienda è TARA-002, una terapia cellulare sperimentale, in fase II di sperimentazione clinica per il trattamento del cancro alla vescica non muscolo-invasivo e delle malformazioni linfatiche. L'azienda sta inoltre sviluppando il cloruro di colina per via endovenosa, una terapia sostitutiva del substrato fosfolipidico per i pazienti che ricevono nutrizione parenterale e fluidi.

Protara Therapeutics, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Protara Therapeutics con la sua capitalizzazione di mercato?
TARA statistiche fondamentali
Capitalizzazione di mercatoUS$276.52m
Utili (TTM)-US$63.31m
Ricavi(TTM)n/a
0.0x
Rapporto P/S
-4.3x
Rapporto P/E

TARA è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Utili e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
TARA Conto economico (TTM)
RicaviUS$0
Costo del fatturatoUS$0
Profitto lordoUS$0
Altre speseUS$63.31m
Utili-US$63.31m

Ultimi utili riportati

Mar 31, 2026

Prossima data di guadagno

n/a

Utile per azione (EPS)-1.13
Margine lordo0.00%
Margine di profitto netto0.00%
Rapporto debito/patrimonio netto0%

Come si è comportato TARA nel lungo periodo?

Vedi performance storica e confronto

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/05/26 12:23
Prezzo dell'azione a fine giornata2026/05/26 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Protara Therapeutics, Inc. è coperta da 10 analisti. 7 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Li Wang WatsekCantor Fitzgerald & Co.
Andrew FeinH.C. Wainwright & Co.
Andres MaldonadoH.C. Wainwright & Co.